RedHill Biopharma Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Public

  • Employees
  • 23

Employees

  • Investments
  • 4

  • Share Price
  • $0.67
  • (As of Tuesday Closing)

RedHill Biopharma General Information

Description

Developer of pharmaceutical drugs intended to treat gastrointestinal diseases, infectious diseases and oncology. The company develops proprietary oral small-molecule drugs with advanced clinical pipelines and United States commercial operations, enabling physicians and patients to access novel therapies for conditions with high unmet need.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 8311 Brier Creek Parkway
  • Suite 105-161
  • Raleigh, NC 27617
  • United States
+1 (984)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Corporate Office
  • 8311 Brier Creek Parkway
  • Suite 105-161
  • Raleigh, NC 27617
  • United States
+1 (984)

RedHill Biopharma Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

RedHill Biopharma Stock Performance

As of 06-Oct-2020, RedHill Biopharma’s stock price is $0.67. Its current market cap is $251M with 375M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.67 $0.67 $0.67 - $0.72 $251M 375M 30K -$0.15

RedHill Biopharma Financials Summary

As of 30-Jun-2026, RedHill Biopharma has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
Revenue 0 286 0 0
EBITDA (8,440) (7,675) 944 (16,535)
Net Income (2,398) (429) (8,268) 23,916
Total Assets 26,274 25,345 18,043 23,047
Total Debt 1,075 1,070 356 1,173
Public Fundamental Data provided by Morningstar, Inc. disclaimer

RedHill Biopharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore RedHill Biopharma‘s full profile, request access.

Request a free trial

RedHill Biopharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of pharmaceutical drugs intended to treat gastrointestinal diseases, infectious diseases and oncology. The com
Drug Discovery
Raleigh, NC
23 As of 2025

Florham Park, NJ
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

RedHill Biopharma Competitors (3)

One of RedHill Biopharma’s 3 competitors is Phathom Pharmaceuticals, a Formerly VC-backed company based in Florham Park, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Phathom Pharmaceuticals Formerly VC-backed Florham Park, NJ
Ironwood Pharmaceuticals Formerly VC-backed Boston, MA
Anatara Lifesciences Formerly VC-backed Adelaide, Australia
You’re viewing 3 of 3 competitors. Get the full list »

RedHill Biopharma Patents

RedHill Biopharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024405493-A1 Combination therapy for inhibition of ebolavirus Pending 20-Dec-2023
EP-4828595-A2 Combination therapy for inhibition of ebolavirus Pending 20-Dec-2023
WO-2025133697-A2 Combination therapy for inhibition of ebolavirus Inactive 20-Dec-2023
WO-2025133697-A3 Combination therapy for inhibition of ebolavirus Inactive 20-Dec-2023
US-12115150-B2 Biomarkers of coronavirus pneumonia Active 15-Dec-2020 A61K31/4409
To view RedHill Biopharma’s complete patent history, request access »

RedHill Biopharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

RedHill Biopharma Investments (4)

RedHill Biopharma’s most recent deal was a Corporate Asset Purchase with Ferring Pharmaceuticals (Rebyota and Clenpiq Commercialization Rights) for . The deal was made on 01-Sep-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Ferring Pharmaceuticals (Rebyota and Clenpiq Commercialization Rights) 01-Sep-2026 Corporate Asset Purchase Buildings and Property
RedHill Biopharma (Global Rights to Movantik) 02-Apr-2020 Corporate Asset Purchase Buildings and Property
RESprotect (RP101) 14-Aug-2014 Corporate Asset Purchase Buildings and Property
Heidelberg Pharma (Worldwide Rights To RHB-107, Except China, Hong Kong, Taiwan & Macau) Corporate Asset Purchase Buildings and Property
To view RedHill Biopharma’s complete investments history, request access »

RedHill Biopharma ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view RedHill Biopharma’s complete esg history, request access »

RedHill Biopharma Exits (1)

RedHill Biopharma’s most recent exit was on 02-Apr-2020 from RedHill Biopharma (Global Rights to Movantik). The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
RedHill Biopharma (Global Rights to Movantik) 02-Apr-2020 Completed
To view RedHill Biopharma’s complete exits history, request access »

RedHill Biopharma FAQs

  • When was RedHill Biopharma founded?

    RedHill Biopharma was founded in 2009.

  • Where is RedHill Biopharma headquartered?

    RedHill Biopharma is headquartered in Raleigh, NC.

  • What is the size of RedHill Biopharma?

    RedHill Biopharma has 23 total employees.

  • What industry is RedHill Biopharma in?

    RedHill Biopharma’s primary industry is Drug Discovery.

  • Is RedHill Biopharma a private or public company?

    RedHill Biopharma is a Public company.

  • What is the current stock price of RedHill Biopharma?

    As of 06-Oct-2020 the stock price of RedHill Biopharma is $0.67.

  • What is the current market cap of RedHill Biopharma?

    The current market capitalization of RedHill Biopharma is $251M.

  • Who are RedHill Biopharma’s competitors?

    Phathom Pharmaceuticals, Ironwood Pharmaceuticals, and Anatara Lifesciences are competitors of RedHill Biopharma.

  • What is RedHill Biopharma’s annual earnings per share (EPS)?

    RedHill Biopharma’s EPS for 12 months was -$0.15.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process